Kite CAR-T gets FDA priority review, Juno shares fall – Nasdaq
Endpoints News |
Kite CAR–T gets FDA priority review, Juno shares fall
Nasdaq The drug is a chimeric antigen receptor T–cell (CAR-T) therapy, developed using a complicated process of extracting immune system T cells from an individual patient, altering their DNA to sharpen their ability to spot and kill cancer cells, and … Kite catches the inside track on the last leg of a race to the finish line with Novartis on a CAR–T first |
